Related Experiment Video
Updated: Aug 1, 2026
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models
Po-Ju Lin1, Yu-Cheng Kuo2,3, Po-Wei Hu4,5
1Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
Background/Aim:
Non-small cell lung cancer is known for its rapid growth and immune evasion, demanding effective therapies targeting both tumor cells and the microenvironment. Magnolol has shown promising anti-tumor effects in various cancers.
Materials And Methods:
CL1-5-F4-bearing mice were divided into control, 40 mg/kg, and 60 mg/kg magnolol groups, once tumors reached 100 mm3 Tumor growth and body weight were monitored biweekly, and after 13 days, mice were euthanized for tumor and organ collection for subsequent staining. Histopathology and serum biochemistry assessed organ toxicity.
Results:
Magnolol dose-dependently suppressed NSCLC progression, with no pathology alterations observed in normal organs. Magnolol-induced apoptosis and cell cycle arrest, evidenced by increased cleaved caspase-3 and decreased cyclin D1/CDK4 levels. It also down-regulated VEGF, FOXP3, and IDO-1 in tumors, implicating tumor microenvironment modulation.
Conclusion:
Magnolol exhibits significant antitumor effects in NSCLC by inducing apoptosis, inhibiting proliferation, and modulating the tumor microenvironment. These results support further investigation of magnolol as a therapeutic adjuvant to enhance NSCLC treatment outcomes.
Insights
Magnolol effectively suppressed non-small cell lung cancer (NSCLC) progression by inducing apoptosis and modulating the tumor microenvironment. This natural compound shows potential as an adjuvant therapy for NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Non-small cell lung cancer (NSCLC) is characterized by rapid growth and immune evasion.
- Effective therapies are needed to target both tumor cells and the tumor microenvironment.
- Magnolol demonstrates potential anti-tumor properties in preclinical cancer models.
Purpose of the Study:
- To evaluate the anti-tumor efficacy of magnolol in a mouse model of NSCLC.
- To investigate the mechanisms underlying magnolol's anti-cancer effects, including apoptosis, cell cycle regulation, and tumor microenvironment modulation.
Main Methods:
- A xenograft mouse model of NSCLC (CL1-5-F4) was treated with varying doses of magnolol.
- Tumor growth, body weight, and organ toxicity were monitored.
- Tumor tissues and organs were collected for histopathological analysis, apoptosis markers, cell cycle proteins, and immune-related factors (VEGF, FOXP3, IDO-1).
Main Results:
- Magnolol demonstrated dose-dependent suppression of NSCLC tumor progression.
- No significant organ toxicity was observed in magnolol-treated groups.
- Magnolol induced tumor cell apoptosis and cell cycle arrest, evidenced by increased cleaved caspase-3 and decreased cyclin D1/CDK4.
- Down-regulation of VEGF, FOXP3, and IDO-1 in tumors suggests modulation of the tumor microenvironment.
Conclusions:
- Magnolol exhibits significant anti-tumor effects in NSCLC.
- The compound acts by inducing apoptosis, inhibiting proliferation, and modulating the tumor microenvironment.
- Magnolol warrants further investigation as a potential therapeutic adjuvant to improve NSCLC treatment outcomes.
